FDA 483 - Chugai Pharma Manufacturing Co. Ltd. (CPMC) - March 29, 2024
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Chugai Pharma Manufacturing Co., Ltd. (CPMC) in Tokyo, Japan, a drug substance manufacturer, was cited with five observations during an FDA inspection. The findings highlight significant concerns including risks of viral cross-contamination in drug substance manufacturing, inadequate protection of laboratory electronic data, and deficiencies in written production and process control procedures. Additionally, the inspection revealed issues with adherence to standard operating procedures, pest control, employee training, and overall facility maintenance, indicating a need for comprehensive corrective actions to ensure product quality and compliance.
ID · ce2105ec-0fa6-423d-a50d-5443677ed1b2